RxDoctor Payments Data

Shaiful Islam, MD

Cardiovascular Disease · Chambersburg, PANPI 1477577526

Payments from drug & device makers

$1,144in general payments, 2019–2025

Across 51 payments — averaging $22.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$308
  • Abbott$200
  • E.r. Squibb & Sons, L.L.C.$177
  • Novartis$93
  • Actelion Pharmaceuticals US, Inc.$64
  • Boston Scientific$52
  • plus $251 from 9 others

What the payments were for

  • Food & beverage$1,12598%
  • Education$182%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,144 in reported general payments places this provider in the 40th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$188,948
Medicare patients
3,333
Services billed
6,384

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban777$813,558
XareltoRivaroxaban111$139,636
EntrestoSacubitril/Valsartan54$85,289
JardianceEmpagliflozin50$65,169
Repatha SureclickEvolocumab52$39,617
MultaqDronedarone Hcl16$29,123
BrilintaTicagrelor20$16,568
Metoprolol Succinate817$14,365
Ranolazine ErRanolazine107$14,355
Atorvastatin Calcium880$10,362
Midodrine Hcl73$5,597
Flecainide Acetate104$4,855
ClopidogrelClopidogrel Bisulfate270$4,067
Diltiazem 24hr Er (Cd)Diltiazem Hcl115$3,909
Valsartan135$3,729

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$45$813,558777 claims
Johnson & JohnsonXarelto$308$139,636111 claims
NovartisEntresto$93$85,28954 claims
Sanofi-aventis U.S. LLCMultaq$50$29,12316 claims
AstraZenecaBrilinta$13$16,56820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Chambersburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →